Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension
An erratum to this article was published (J Clin Endocrinol Metab, 17 Mar 2026 ↗)
Authors' conclusion
Through week 110 of the PaTH Forward trial, PTH replacement therapy with palopegteriparatide was associated with significant improvements in disease-specific symptoms and impacts on daily functioning and well-being, as well as general health-related QoL.
Study context
- Population
- Adults with chronic hypoparathyroidism
- Comparison
- Palopegteriparatide, change from baseline
- Primary endpoint
- PROs: disease-specific symptoms and impacts on functioning and well-being (Hypoparathyroidism Patient Experience Scales (HPES)); general health-related QoL (SF-36v2)
Methodological detailsphase 2, 4-week randomized, double-blind, placebo-controlled period, open-label extension through week 266, patient-reported outcomes (PROs) collected at baseline, weeks 4, 12, 26, 58 and annually to trial end; descriptive statistics and Mixed Models for Repeated Measures
- Phase 2
- 4-week randomized, double-blind, placebo-controlled period
- Open-label extension through week 266
- PROs collected at baseline, weeks 4, 12, 26, 58 and annually to trial end; descriptive statistics and Mixed Models for Repeated Measures
Primary result
As reported in the abstract
HPES symptoms and impacts on daily functioning and well-being · week 12, sustained through week 110
- Significant improvements from baseline at week 12, sustained through week 110
- Mean changes in PROs met thresholds for clinically meaningful within-patient improvement
Further findings
General health-related quality of life (QoL) (SF-36v2)
- Significant improvements in SF-36v2 scores
PRO changes by demographics and patient characteristics
- Results generally similar across demographics and patient characteristics
Original publication
Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension. J Clin Endocrinol Metab. Published 9 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →